ArticleClinical ophthalmology (Auckland, N.Z.)2026
Efficacy and Safety of an Indian Bevacizumab BIOSimilar (BEVATAS) for Treatment-Naïve Diabetic Macular Edema (BIOS-DME Study).
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the anatomical and functional efficacy of bevacizumab biosimilar (Bevatas Patients and Methods: This retrospective observational study included 123 eyes of patients with center-involving DME (CI-DME) treated with intravitreal biosimilar of bevacizumab (IVBb) between January 2022 and December 2025. Eyes received three loading doses followed by pro-re-nata regimen with supplemental focal laser as needed. Best-corrected visual acuity (BCVA), central macular thickness (CMT), intraocular pressure, (IOP), and optical coherence tomography (OCT) biomarkers were assessed at baseline and at months 1, 2, 3, 6, and 12. Treatment burden and safety outcomes were recorded. Results: Mean visual acuity improved from 0.591 ± 0.276 logMAR at baseline to 0.249 ± 0.079 logMAR at month 12, representing a gain of 0.342 logMAR ( Conclusion: Bevacizumab biosimilar produces meaningful visual and anatomical improvement in CI-DME in a real-world Indian setting. The modest injection frequency reflects practical treatment patterns in resource-limited environments. IVBb represents an accessible and affordable anti-vascular endothelial growth factor (anti-VEGF) option for DME management in India and similar healthcare contexts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.